Medicine
Cisatracurium 200 mg/20 mL injection
Cisatracurium 200 mg/20 mL injection is a generic prescription medicine for intravenous use, made by 13 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Refrigerate cisatracurium besylate USP at 2°C to 8°C (36°F to 46°F) in the…
Key facts
- Active ingredient (INN)
- Cisatracurium
- Brand
- Sold under the generic name
- Strength
- 200 mg/20 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 10 vials of 20 mL, 1 vial of 20 mL, 10 boxes of 20 mL and 13 more
- Manufacturers
- Zydus LifesciencesIndiaCamber PharmaceuticalsIndiaCaplin SterilesIndiaGland PharmaIndiaMeitheal PharmaceuticalsSomerset TherapeuticsArmas PharmaceuticalsAvenacyFresenius KabiHikma Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Refrigerate cisatracurium besylate USP at 2°C to 8°C (36°F to 46°F) in the carton to preserve potency. DO NOT FREEZE. Upon removal from the refrigeration, use within 21 days even if re-refrigerated. Protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 July 2012
- Identifiers
- RxCUI 199212, 1730194, 199211DailyMed set ID dd078343-1f43-4405-8048-cf6c4f456549, e145a40e-b046-4064-b35e-0da40ff3703e, 49185e78-d244-4426-90ef-ad109824eddb +12NDC 72485-513, 72785-0009, 70436-114 +11Application ANDA217725, ANDA212171, ANDA216539 +8
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 vial in 1 carton / 20 mL in 1 vial | 70710-1534-6 | Zydus LifesciencesIndia | 12 February 2020 |
| 10 vial in 1 carton / 20 mL in 1 vial | 72785-0009-6 | Zydus LifesciencesIndia | 12 February 2020 |
| 10 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 31722-312-10 | Camber PharmaceuticalsIndia | 4 May 2026 |
| 1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 65145-137-01 | Caplin SterilesIndia | 17 January 2025 |
| 1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 68083-487-01 | Gland PharmaIndia | 19 March 2025 |
| 10 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 71288-713-21 | Meitheal Pharmaceuticals | 31 October 2019 |
| 10 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 71288-713-96 | Meitheal Pharmaceuticals | 31 October 2019 |
| 10 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 72485-513-10 | Armas Pharmaceuticals | 15 January 2025 |
| 10 vial in 1 carton / 20 mL in 1 vial | 63323-418-20 | Fresenius Kabi | 26 February 2015 |
| 10 vial in 1 carton / 20 mL in 1 vial | 0143-9160-10 | Hikma Pharmaceuticals | 17 March 2025 |
| 10 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 0409-1103-01 | Hospira | 2 December 2019 |
| 10 box in 1 carton / 1 vial in 1 box / 20 mL in 1 vial | 0781-3153-95 | Sandoz | 16 July 2012 |
| 10 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 70436-114-82 | Slate Run Pharmaceuticals | 2 September 2021 |
| 1 vial in 1 carton / 20 mL in 1 vial | 70069-151-01 | Somerset Therapeutics | 4 February 2019 |
| 10 vial in 1 carton / 20 mL in 1 vial | 70069-151-10 | Somerset Therapeutics | 4 February 2019 |
| 10 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 83634-655-20 | Avenacy | 15 August 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 15 December 1995 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Cisatracurium
Clinical summary
Cisatracurium is a nondepolarizing neuromuscular blocker indicated as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age, among other approved uses. MedsAcross supplies Cisatracurium for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CisatracuriumFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cisatracurium Besylate prescribing information (Hospira) · U.S. National Library of Medicine, DailyMed
Need Cisatracurium 200 mg/20 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.